Why Annexon Inc. (ANNX) Went Down On Thursday?

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Annexon Inc. (NASDAQ:ANNX) stands against other stocks that fall behind amid market optimism.

Wall Street’s main indices rebounded from hefty losses on Wednesday after President Donald Trump announced that the US will pause the imposition of higher tariffs on 75 countries for 90 days.

In a post on Truth Social, Trump said that more than 75 countries have called to negotiate and have not retaliated in any way.

“I have authorized a 90-day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effective immediately,” he noted.

Following the announcement, the Dow Jones jumped by 7.87 percent, the S&P 500 surged by 9.52 percent, and the tech-heavy Nasdaq soared by 12.16 percent.

Despite the overall market optimism, 10 companies, predominantly in the biopharmaceutical sector, registered losses amid the lack of fresh developments to spark buying appetite.

In this article, we listed Wednesday’s 10 worst performers and detailed the reasons behind their drop.

To come up with the list, we considered only the stocks with over $1 million in trading volume.

A biopharmaceutical expert reviewing Phase II/III clinical trials of a new therapy for ALS.

Annexon Inc. fell for a fifth straight day on Wednesday, losing 7.79 percent to end at $1.42 apiece as investor funds flocked to higher-yielding stocks amid the company’s lack of catalyst to boost buying appetite.

On Tuesday, the biopharmaceutical company presented data for its late-stage targeted therapy for Guillain-Barré Syndrome (GBS). Called the tanruprubart, the phase 3 trial was said to have provided positive results in patients with GBS by shutting down neuroinflammation and nerve damage.

Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade. With a single infusion, tanruprubart halts ongoing neuroinflammation and nerve damage in the acute phase of GBS to improve and expedite overall recovery.

GBS is a neuromuscular emergency that affects at least 150,000 people worldwide each year, with no FDA-approved therapies.

“Tanruprubart has the potential to help patients get better faster and ultimately reach a better state of health than with existing therapies or without treatment, while significantly reducing the burden of care,” the company said.

Overall, ANNX ranks 9th on our list of stocks that fall behind amid market optimism. While we acknowledge the potential of ANNX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ANNX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.